SMS Pharmaceuticals Ltd — Capital/Financing Update 2025

Jun 27, 2025

==> picture [241 x 158] intentionally omitted <==

Date: 27[th] June 2025

To The Manager, The Manager, Corporate Filings Department, Listing Compliance Department, BSE Limited, National Stock Exchange of India Ltd. Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, Dalal Street, Bandra-Kurla Complex, Bandra (E), Mumbai- 400 001. Mumbai - 400 051.

Security Code: 532815 Symbol: SMSPHARMA

Dear Sir/Madam,

Subject: Intimation under Regulation 30 read with Schedule III of SEBI LODR Regulations, 2015 - Investments in Subsidiary Company by way of subscription towards Rights Issue

In terms of Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this is to inform that the Subsidiary Company “SMS Peptides Private Limited” has allotted 30,00,000 equity shares of Rs. 10/- each amounting to Rs. 3,00,00,000/-, to the Company. Pursuant to this the holding of the Company in its Subsidiary has been increased from 93% to 99.98% of the equity share capital of SMS Peptides Private Limited.

The disclosure as required under Schedule III of the Listing Regulations read with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 November 11, 2024 is enclosed as Annexure-1 to this letter.

This is for your information and records.

Thanking you Yours faithfully

For SMS Pharmaceuticals Limited

THIRUMALES Digitally signed by THIRUMALESH TUMMA H TUMMA Date: 2025.06.27 16:39:19 +05'30'

Thirumalesh Tumma Company Secretary

Annexure – 1

Details as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular No SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Sr.No.	Particulars	Details
1.	Name of the target entity, details inbrief such as size, turnover etc.,	M/s. SMS Peptides Private Limited(SMS Peptides), Subsidiary Company,incorporated under Companies Act,2013. Authorised Share Capital of theCompany is Rs.10,00,00,000/- dividedinto 1,00,00,000 equity shares ofRs.10/- each and the paid-up sharecapitaloftheCompanyisRs.3,01,00,000/-dividedinto30,10,000 equity shares of Rs.10/-each.
2.	Whether the acquisition would fallwithin related party transaction(s)and whether the promoter/ promotergroup/ group companies have anyinterest in the entity being acquired?If yes, nature of interest and detailsthereof and whether the same is doneat “arm’s length”	Yes,sinceSMSpeptidesisasubsidiaryCompanyofSMSPharmaceuticals Limited and wouldfall within the purview of relatedparty transaction in terms of SEBI(LODR) Regulations, 2015.The Company’s interest is limitedonly to the extent of its shareholdingThe said transaction is at arm'slength.
3.	industry to which the entity beingacquired belongs	SMSPeptidesbelongstoPharmaceutical Industry.

4.	objects and impact of acquisition(includingbutnotlimitedto,disclosure of reasons for acquisitionof target entity, if its business isoutside the main line of business ofthe listed entity	Toprocureinitialequipments,machineriestocarryonR&Dactivities related to the SubsidiaryCompany
5.	brief details of any governmental orregulatory approvals required for theacquisition	None
6.	indicative time period for completionof the acquisition	The subsidiary company allotted30,00,000 equity shares of Rs.10/-each on 27.06.2025
7.	consideration-whethercashconsideration or share swap or anyother form and details of the same	Cash
8.	cost of acquisition and/or the price atwhich the shares are acquired	Cost of acquisition : Rs.3,00,00,000/-Share price : Rs.10/- each at par.
9.	Percentage of shareholding / controlacquired and / or number of sharesacquired:	SMS Pharmaceuticals Limited washolding 93% stake in SMS Peptidesandafterthisinvestmentthepercentage is increased to 99.98%.
10.	brief background about the entityacquired in terms of products/line ofbusinessacquired,dateofincorporation, history of last 3 yearsturnover,countryinwhichtheacquired entity has presence and anyother significant information (in brief)	SMSPeptidesisasubsidiaryCompany incorporated in November,2024 and yet to commence itsbusiness operations.DateofIncorporation:01stNovember, 2024Country in which the acquired entityhas presence: IndiaLast 3 years turnover: Not Applicable